Research Topics
| Michael W KuzniewiczSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Variation in ICU risk-adjusted mortality: impact of methods of assessment and potential confoundersMichael W Kuzniewicz
Institute for Health Policy Studies, Neonatology, University of California San Francisco, San Francisco, CA 94143 0748, USA
Chest 133:1319-27. 2008..In this study, we determine whether a substantial variation in ICU mortality performance still exists in modern ICUs, and compare the predictive accuracy, reliability, and data burden of existing ICU risk-adjustment models...
Interaction of hemolysis and hyperbilirubinemia on neurodevelopmental outcomes in the collaborative perinatal projectMichael Kuzniewicz
University of California, 533 Parnassus Ave, UC Hall U585 F, Box 0748, San Francisco, CA 94143 0748, USA
Pediatrics 123:1045-50. 2009..Our objective was to reanalyze data from the Collaborative Perinatal Project to investigate whether bilirubin is more neurotoxic in newborns with a positive direct antiglobulin test...
Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy useMichael W Kuzniewicz
Division of Neonatology, Department of Pediatrics, University of California, San Francisco, CA 94143 0748, USA
Pediatrics 124:1031-9. 2009..The goal was to assess the impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use...
Numbers needed to treat with phototherapy according to American Academy of Pediatrics guidelinesThomas B Newman
Department of Epidemiology and Biostatistics, UCSF Box 0560, San Francisco, CA 94143, USA
Pediatrics 123:1352-9. 2009..Our aims were to estimate the efficacy of hospital phototherapy for neonatal jaundice and the number needed to treat to prevent one infant from reaching the exchange transfusion level...
Relationship between discharge practices and intensive care unit in-hospital mortality performance: evidence of a discharge biasEduard E Vasilevskis
Philip R Lee Institute for Health Policy Studies and Division of General Internal Medicine, University of California San Francisco, CA, USA
Med Care 47:803-12. 2009..This measure does not account for deaths occurring after transfer to another hospital or soon after discharge and therefore, may be biased...
Predictors of early postdischarge mortality in critically ill patients: a retrospective cohort study from the California Intensive Care Outcomes projectEduard E Vasilevskis
Philip R Lee Institute for Health Policy Studies, University of California at San Francisco, San Francisco, CA, USA
J Crit Care 26:65-75. 2011..However, early postdischarge mortality contributes significantly to overall 30-day mortality. Factors associated with early postdischarge mortality are unknown...
Total serum bilirubin exceeding exchange transfusion thresholds in the setting of universal screeningValerie J Flaherman
Department of Pediatrics, University of California, San Francisco, CA, USA
J Pediatr 160:796-800.e1. 2012..To describe the incidence and predictors of total serum bilirubin (TSB) levels that meet or exceed American Academy of Pediatrics (AAP) exchange transfusion (ET) thresholds in the setting of universal screening...
Risk factors for severe hyperbilirubinemia among infants with borderline bilirubin levels: a nested case-control studyMichael W Kuzniewicz
Division of Neonatology, University of California San Francisco, San Francisco, CA, USA
J Pediatr 153:234-40. 2008..To estimate the effect of phototherapy and other predictors on the risk of total serum bilirubin (TSB) >or= 25 mg/dL in infants with a TSB of 17 to 22.9 mg/dL at age >or= 48 hours...
Black race is not protective against hazardous bilirubin levelsAndrea C Wickremasinghe
Department of Pediatrics, University of California, San Francisco, CA Electronic address
J Pediatr 162:1068-9. 2013..We found that although black infants have a lower risk of developing total serum bilirubin levels ≥20 mg/dL than white infants, they appear at greater risk of developing levels ≥30 mg/dL...
